Compare OPTT & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPTT | GOVX |
|---|---|---|
| Founded | 1984 | 2001 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.4M | 3.8M |
| IPO Year | 2006 | N/A |
| Metric | OPTT | GOVX |
|---|---|---|
| Price | $0.19 | $0.80 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $1.50 | $1.00 |
| AVG Volume (30 Days) | ★ 5.4M | 201.0K |
| Earning Date | 03-17-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.83 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,861,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $221.57 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.08 | N/A |
| 52 Week Low | $0.13 | $0.12 |
| 52 Week High | $0.72 | $4.40 |
| Indicator | OPTT | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 42.44 | 40.83 |
| Support Level | $0.13 | $0.64 |
| Resistance Level | $0.45 | $2.00 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 89.40 | 42.26 |
Ocean Power Technologies Inc provides intelligent maritime solutions and services that enable safer, cleaner, and more productive ocean operations for the defense and security, oil and gas, science and research, and offshore wind markets. It provides ocean data collection and reporting, marine power, offshore communications, and Maritime Domain Awareness System (MDAS) products, integrated solutions, and consulting services. The company offers its products and services to a wide range of customers, including those in government and offshore energy, oil and gas, construction, wind power, and other industries. The company has operations in North and South America, Europe, Asia and Australia.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.